explore -WSS

explore

author：focus 2025-09-27 23:51:55 - browse：31

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： BIO selects John Crowley as new CEO

explore

WSS

30 years of 'Listening to Prozac'

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Despite FDA concern, risk that CAR

With clinical trial data readouts, here's how to spot spin

Can CDC director Mandy Cohen drive consensus in Washington?

FDA investigates CAR

entertainment

explore

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Psychedelics group wrestles with new pharma identity

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

BioMarin wins approval for gene therapy to treat hemophilia A

ReNAgade cuts staff seven months after raising $300 million

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Pediatric cancer treatments threatened by a new FDA policy

leisure time

Does aspartame cause cancer? What new WHO guidance says

As biotech industry slumps, bioscience job market is upside down

Will the market for weight loss drugs really reach $100 billion?

Fetal surgery at risk from Dobbs and new abortion restrictions

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Celiac disease study examines precisely how gluten triggers injury

explore

knowledge

explore

hotspot